Japan stock market week to Nov 14

19 September 2013

Tokyo extended gains in the week ended May 5 (three trading days only because April 29 and May 5 were national holidays in Japan). The Nikkei  225 finished 1.1% higher, to close at the 14,000 level, a four-month  high, while the Topix index rose 1.2%. Investors were encouraged by the  weaker yen against the US dollar and the solid performance of New York  markets with the recognition that interest cuts by the Federal Reserve  Board are likely to pause in the near term. High technology issues and  financial stocks drew buying attention. However, the overall market was  rather directionless because of the string of "Golden Week" holidays and  forthcoming earnings reports after these. The pharmaceutical index  inched up 0.3%, underperforming the market.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight